Step Pharma to present a poster on STP938 at American Society of Hematology conference

Paris, France, December 1st 2020 – Step Pharma SAS, in collaboration with Sygnature Discovery, has been selected to present a poster named "STP938, a Novel, Potent and Selective Inhibitor of CTP Synthase 1 (CTPS1) Is a Targeted Therapy Specifically Blocking De Novo Nucleotide Synthesis in Lymphomas and Leukemias" at the American Society of Hematology (ASH) conference starting December 5th.

Step Pharma selected by a panel of 15 European investors as a winner in the MATWIN OUI event

Paris, France, 23 October 2020 – Step Pharma SAS have been ranked 1st among eleven cancer research companies by the MATWIN second OUI (Oncology Upward Investment) investor event, designed to help secure financial backing for promising innovations. More info (Matwin press release).